TLDRCBOE stock falls 0.90% to $346.06 as the company challenges CFTC derivatives approval.Cboe joins Citadel Securities in a legal fight over perpetual stock and ETF derivatives.Cboe challenges CFTC approval, arguing securities products require stronger oversight.CBOE shares lose $3.16 as the company backs legal action against the CFTC’s decision.Cboe raises regulatory concerns over perpetual derivatives tied to U.S. stocks and ETFs.Cboe Global Markets (CBOE) stock declined 0.90% to $346.06, losing $3.16 during the latest trading session. The decline followed a sharp morning sell-off, although shares recovered some losses later. Meanwhile, Cboe announced its support for legal action challenging the Commodity Futures Trading Commission’s approval of perpetual derivatives tied to U.S. stocks and exchange-traded funds.Cboe Global Markets, Inc., CBOECboe Joins Legal Challenge Against CFTC ApprovalCboe Global Markets joined the Capital Markets Alliance (CMA) in challenging the CFTC’s approval of perpetual derivatives. The alliance also includes Citadel Securities and the Healthy Markets Association. Together, these organizations seek to challenge the regulatory basis for allowing these products within CFTC-supervised markets.The legal action focuses on perpetual derivatives linked to individual U.S. stocks and exchange-traded funds. These contracts allow market participants to gain exposure to underlying securities without directly owning them. However, Cboe argues that securities-related products should operate under established securities market regulations.The company maintains that existing securities laws provide specific protections for market participants. Furthermore, it argues that placing securities products outside registered securities platforms could weaken those safeguards. The legal challenge therefore seeks to address concerns about regulatory oversight and the treatment of these financial products.Cboe Raises Concerns Over Securities Market RegulationCboe Global Markets argues that the CFTC’s recent approvals depart from the regulatory framework governing U.S. securities markets. The company maintains that Congress established specific requirements for securities trading. Consequently, it believes regulators should apply those requirements to products linked to individual securities and broader indices.The company also raised concerns about regulatory arbitrage across different trading platforms. According to its position, offering securities-related products through CFTC-regulated platforms could bypass certain federal and state requirements. Cboe argues that this approach could weaken established market safeguards and oversight standards.Cboe also emphasized its history of operating within competitive financial markets. The exchange operator has more than five decades of experience across global trading markets. Additionally, the company stated that competition and financial innovation do not conflict with its position on regulatory compliance. It maintains that new products should follow the appropriate legal framework.Legal Action Could Shape Perpetual Derivatives OversightThe Capital Markets Alliance is seeking injunctive relief through its legal action against the CFTC’s approvals. This request aims to address the uncertainty surrounding the regulator’s decisions. Furthermore, the alliance wants the courts to examine whether these products fall under the appropriate regulatory authority.The dispute also raises broader questions about the boundaries between securities and derivatives regulation. The CFTC oversees derivatives markets, while securities trading falls under a separate regulatory framework. Therefore, determining which rules apply remains central to the legal challenge.Cboe Global Markets continues to operate across several major financial market segments. Its business includes options exchanges, futures trading, equities markets, and clearing services. However, the regulatory dispute introduces another issue for the company’s market position. Cboe’s opposition reflects its stated preference for consistent oversight across securities-related products. The post Cboe Global Markets (CBOE) Stock: Falls as Firm Opposes CFTC Derivatives Approval appeared first on Blockonomi.